Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hepatocellular carcinoma

Sorafenib—for once age is not an issue

Nature Reviews Gastroenterology & Hepatology volume 11, pages 273–274 (2014)Cite this article

Subjects

Are some patients with hepatocellular carcinoma just too old to be treated? More specifically, should the age of a patient influence the way sorafenib is prescribed? A new study has tried to address these questions, providing helpful information to guide clinicians making these decisions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. European Association for the Study of the Liver & European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).

  2. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

    Article  CAS  Google Scholar 

  3. Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34 (2009).

    Article  CAS  Google Scholar 

  4. Jo, M. et al. Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. Hepatol. Res. http://dx.doi.org/10.1111/hepr.12308.

  5. Iavarone, M. et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54, 2055–2063 (2011).

    Article  CAS  Google Scholar 

  6. Cho, J. Y. et al. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int. 33, 950–957 (2013).

    Article  CAS  Google Scholar 

  7. Al Hasani, F. et al. Factors affecting screening for hepatocellular carcinoma. Ann. Hepatol. 13, 204–210 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hepatology, University Clinic of Visceral Surgery and Medicine, Inselspital, Bern, CH-3010, Switzerland

    Jean-François Dufour

Authors
  1. Jean-François Dufour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-François Dufour.

Ethics declarations

Competing interests

J.-F.D has been an advisor for Bayer, BMS, Gilead Science, Janssen Cilag, Jennerex, Merck, Novartis and Roche, and has spoken and taught for Bayer, Boehringer-Ingelheim, Novartis and Roche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dufour, JF. Sorafenib—for once age is not an issue. Nat Rev Gastroenterol Hepatol 11, 273–274 (2014). https://doi.org/10.1038/nrgastro.2014.48

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2014.48

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing